NCT03547037View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

July 4, 2022

Study Completion Date

July 4, 2022

Conditions
Neoplasm
Interventions
DRUG

JNJ-63723283

JNJ-63723283 will be administered intravenously.

DRUG

Erdafitinib

Erdafitinib will be administered orally.

Trial Locations (2)

104 0045

National Cancer Center Hospital, Chūōku

277 8577

National Cancer Center Hospital East, Kashiwa

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT03547037 - A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers | Biotech Hunter | Biotech Hunter